Arica White, Lisa C. Richardson, Chunyu Li, and Donatus U. Ekwueme are with the Division of Cancer Prevention and Control, National Center for Chronic Disease and Health Promotion, Centers for Disease Control and Prevention (CDC), Atlanta, GA. Judith S. Kaur is with the Mayo Clinic, Rochester, MN.
Am J Public Health. 2014 Jun;104 Suppl 3(Suppl 3):S432-8. doi: 10.2105/AJPH.2013.301720. Epub 2014 Apr 22.
We compared breast cancer death rates and mortality trends among American Indian/Alaska Native (AI/AN) and White women using data for which racial misclassification was minimized.
We used breast cancer deaths and cases linked to Indian Health Service (IHS) data to calculate age-adjusted rates and 95% confidence intervals (CIs) by IHS-designated regions from 1990 to 2009 for AI/AN and White women; Hispanics were excluded. Mortality-to-incidence ratios (MIR) were calculated for 1999 to 2009 as a proxy for prognosis after diagnosis.
Overall, the breast cancer death rate was lower in AI/AN women (21.6 per 100,000) than in White women (26.5). However, rates in AI/ANs were higher than rates in Whites for ages 40 to 49 years in the Alaska region, and ages 65 years and older in the Southern Plains region. White death rates significantly decreased (annual percent change [APC] = -2.1; 95% CI = -2.3, -2.0), but regional and overall AI/AN rates were unchanged (APC = 0.9; 95% CI = 0.1, 1.7). AI/AN women had higher MIRs than White women.
There has been no improvement in death rates among AI/AN women. Targeted screening and timely, high-quality treatment are needed to reduce mortality from breast cancer in AI/AN women.
我们使用最小化种族分类错误的数据,比较了美国印第安人/阿拉斯加原住民(AI/AN)和白人女性的乳腺癌死亡率和死亡率趋势。
我们使用乳腺癌死亡病例和与印第安卫生服务(IHS)数据相关的病例,按 IHS 指定的区域计算了 1990 年至 2009 年 AI/AN 和白人女性的年龄调整率和 95%置信区间(CI);排除了西班牙裔。1999 年至 2009 年的死亡率与发病率比(MIR)被计算出来作为诊断后预后的替代指标。
总体而言,AI/AN 女性的乳腺癌死亡率(21.6/100,000)低于白人女性(26.5/100,000)。然而,在阿拉斯加地区,AI/AN 的年龄在 40 岁至 49 岁之间,以及在南部平原地区的年龄在 65 岁及以上的女性中,死亡率高于白人。白人死亡率显著下降(年百分比变化[APC]=-2.1;95%置信区间[CI]=-2.3,-2.0),但区域和总体 AI/AN 死亡率保持不变(APC=0.9;95% CI=0.1,1.7)。AI/AN 女性的 MIR 高于白人女性。
AI/AN 女性的死亡率没有改善。需要有针对性的筛查和及时、高质量的治疗,以降低 AI/AN 女性乳腺癌的死亡率。